BCL
ABBV icon

Burnham & Co LLC’s AbbVie ABBV Stock Holding History

Burnham & Co LLC’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.25M Buy
+12,903
New +$2.78M 2.62% 13

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Burnham & Co LLC's ABBV Position: Q2 2026 in Review

Burnham & Co LLC opened a new position in AbbVie (ABBV) in Q2 2026: 12,903 shares worth $3.25M. The stake represents 2.62% of the portfolio and ranks #13 among its holdings.

3,747 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Burnham & Co LLC held 12,903 shares of AbbVie worth $3.25M as of Q2 2026.
  • AbbVie was a new Burnham & Co LLC position in Q2 2026.
  • AbbVie made up 2.62% of Burnham & Co LLC's portfolio in Q2 2026, its #13 holding.
  • 3,747 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Burnham & Co LLC's 13F filing for Q2 2026, filed 11 Aug 2026.